* The Brazilian government has signed a US$127m agreement to locally produce a coronavirus (Covid-19) vaccine that has been developed by the University of Oxford in the United Kingdom and is licensed to British-Swedish pharmaceutical company AstraZeneca. The ChAdOx1 nCoV-19 vaccine, currently being trialled in Brazil in partnership with the Universidade Federal de São Paulo (Unifesp), is considered a leading candidate in the global race to develop and license a Covid-19 vaccine. Under the terms of the agreement, Brazil assumes the costs and risks of manufacturing 30m doses of the vaccine in December 2020 and January 2021, and will be able to produce up to 100m doses if all trials are completed and licensure requirements are passed. The vaccine will be manufactured by the Fundação Oswaldo Cruz (Fiocruz), a leading scientific research institute linked to the Brazilian government.
End of preview - This article contains approximately 141 words.
Subscribers: Log in now to read the full article
Not a Subscriber?
Choose from one of the following options